Baseline serum levels of Immunoglobulin A (IgA) anti-cyclic citrullinated protein antibodies in early rheumatoid arthritis predict radiographic progression after 11 years of treatment: a secondary analysis of the CIMESTRA study
Authors' conclusion
ACPA IgA and IgG were weakly associated with disease activity in early RA. RA patients with a ΔTSS ≥ 5 after 11 years of treatment had higher ACPA IgG and ACPA IgA levels at baseline; however, none of the ACPA subtypes was superior in predicting long-term radiographic progression.
Study context
- Population
- Patients with early rheumatoid arthritis (RA)
- Participants
- 97 patients
- Comparison
- ACPA IgA subtypes vs ACPA IgG
- Primary endpoint
- Association of ACPA IgA subtypes with disease activity and long-term radiographic outcomes (total Sharp score (TSS)), compared with ACPA IgG
- Follow-up
- 11 years
Primary result
As reported in the abstract
Prediction of radiographic progression (ΔTSS ≥ 5 from 0 to 11 years)
| Group | Positive likelihood ratio |
|---|---|
| ACPA IgA | 3.7 |
| ACPA IgG | 4.0 |
Positive likelihood ratio
ACPA IgA3.7
ACPA IgG4.0
Further findings
Disease activity · baseline
- Both ACPA IgA and IgG levels at baseline weakly associated with disease activity markers
Characteristics of ACPA IgA positivity
- All patients with ACPA IgA also had ACPA IgG
- ACPA IgA positivity associated with IgM rheumatoid factor (IgM-RF) and male gender
Original publication
Baseline serum levels of IgA anti-cyclic citrullinated protein antibodies in early rheumatoid arthritis predict radiographic progression after 11 years of treatment: a secondary analysis of the CIMESTRA study. Scand J Rheumatol. Published 18 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →